OranssiBio is a CDMO specializing in cell and gene therapy solutions. Based in Shanghai, China, the company offers comprehensive services covering process development, analytical method development, GMP manufacturing, quality control, stability testing, and CMC regulatory support. OranssiBio's platforms include cell therapies (T cells and NK cells), AAVs, lentivirus, plasmid DNA, and exosomes. Their facilities comply with U.S. and EU GMP standards, featuring scalable, serum-free suspension processes with single-use bioreactors up to 200 L, automated purification, and fill/finish operations.